Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low CBG Clear all
Completed Phase 3 Interventional Results available

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

NCT02006888
View directory record Official record
Conditions
Inflammation, Cataracts
Interventions
IBI-10090, Placebo
Drug
Lead sponsor
ICON Bioscience Inc
Industry
Eligibility
40 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lancaster, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

NCT00933400
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions
CT Coronary Angiography (CTCA), Traditional Strategy
Diagnostic Test · Procedure
Lead sponsor
American College of Radiology
Other
Eligibility
30 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

NCT00239681
View directory record Official record
Conditions
Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions
Rosuvastatin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years and older
Enrollment
17,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
431
States / cities
Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 17, 2026, 5:28 AM EDT
Enrolling by invitation Not applicable Interventional

Closed Sinus Augmentation With a Calcium Phosphosilicate Putty

NCT06507709
View directory record Official record
Conditions
Dental Implant, Maxillary Sinus Floor Augmentation
Interventions
Low volume CBCT
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

NCT00244855
View directory record Official record
Conditions
Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Marginal Zone Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
pharmacological study, rituximab, dexamethasone, laboratory biomarker analysis
Other · Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 1 Interventional Results available

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

NCT01241903
View directory record Official record
Conditions
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions
rosuvastatin, placebo
Drug
Lead sponsor
Susan Smyth
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Early Phase 1 Interventional

Zero Sodium Peritoneal Dialysate Protocol Pilot Study

NCT03801226
View directory record Official record
Conditions
Potential Applications for Heart Failure, Volume Overload
Interventions
Two-hour dwell with 10% dextrose in sterile water, Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 17, 2026, 5:28 AM EDT
Recruiting Phase 4 Interventional

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

NCT06003348
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

NCT00104572
View directory record Official record
Conditions
Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions
Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU
Drug · Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

VELCADE,Rituximab,Cyclophosphamide and Decadron

NCT00413959
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Interventions
VELCADE®, Rituximab, Cyclophosphamide, Decadron
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease

NCT04019379
View directory record Official record
Conditions
Phosphorus and Calcium Disorders, Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Diseases
Interventions
High Phosphorus Diet, Low Phosphorus Diet
Other
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?

NCT00700804
View directory record Official record
Conditions
Dietary Proteins
Interventions
High Protein Diet, Low Protein Diet
Behavioral
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
50 Years to 80 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

NCT00065806
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atorvastatin, Placebo atorvastatin
Drug
Lead sponsor
Laura Schanberg
Other
Eligibility
10 Years to 21 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

NCT00064753
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease, Death
Interventions
High Dose Multivitamin, Low Dose Multivitamin
Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
35 Years to 75 Years
Enrollment
4,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 17, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

NCT04633811
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight Loss, Optifast VLCD Program, Optifast VLCD Transition Phase, Low Oxalate Diet after Weight Loss, Oral load of oxalate and sucralose after Weight Loss
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Therapeutic Diets in Alzheimer's Disease

NCT03860792
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Ketogenic Diet, Therapeutic Lifestyles Changes Diet
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Thymus Transplantation Dose in DiGeorge #932

NCT00576836
View directory record Official record
Conditions
DiGeorge Anomaly, DiGeorge Syndrome, Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions
Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation
Biological · Other
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

NCT02620865
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
Aldesleukin, Antibody Therapy, Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Sargramostim
Biological · Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01155583
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 17, 2026, 5:28 AM EDT
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry

NCT00297219
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis
Interventions
Low dialysate calcium, high dialysate calcium
Drug
Lead sponsor
Ege University
Other
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00002865
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Calcium Metabolism in Mexican American Adolescents

NCT01277185
View directory record Official record
Conditions
Osteoporosis
Interventions
Low Calcium Diet, High Calcium Diet
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
12 Years to 15 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 17, 2026, 5:28 AM EDT